DMAE as sole agent for the treatment of mild cognitive impairment
US8207218B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 31, 2007 |
| Grant date | Jun 26, 2012 |
| Priority date | — |
| Expiry date | Mar 9, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use, as sole active ingredient, of dimethylaminoethanol (DMAE) in free form or in the form of salts or of esters and also of hydrates and solvates thereof, for the manufacture of a medicament for use in the treatment of a non-dementia mild cognitive impairment characterized by an amnestic syndrome of hippocampal type.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.